prikaz prve stranice dokumenta Pojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke
  Download
PDF 12.5 MB
master's thesis
Pojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke
2017. urn:nbn:hr:152:222472
Banović, Ana
Josip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek

Cite this document

Banović, A. (2017). Pojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke (Master's thesis). Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek. Retrieved from https://urn.nsk.hr/urn:nbn:hr:152:222472

Banović, Ana. "Pojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2017. https://urn.nsk.hr/urn:nbn:hr:152:222472

Banović, Ana. "Pojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke." Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, 2017. https://urn.nsk.hr/urn:nbn:hr:152:222472

Banović, A. (2017). 'Pojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke', Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, accessed 20 November 2024, https://urn.nsk.hr/urn:nbn:hr:152:222472

Banović A. Pojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke [Master's thesis]. Osijek: Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek; 2017 [cited 2024 November 20] Available at: https://urn.nsk.hr/urn:nbn:hr:152:222472

A. Banović, "Pojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke", Master's thesis, Josip Juraj Strossmayer University of Osijek, Faculty of Medicine Osijek, Osijek, 2017. Available at: https://urn.nsk.hr/urn:nbn:hr:152:222472

Please login to the repository to save this object to your list.
Metadata
TitlePojavnost HER1 receptora i e-cadherina u trostruko negativnom karcinomu dojke
Title (english)HER1 receptor overexpression and e-cadherin expression in the triple negative breast carcinoma.
AuthorAna Banović
MentorBranko Dmitrović (mentor)
Committee memberSven Kurbel (predsjednik povjerenstva)
Committee memberIlijan Tomaš (član povjerenstva)
Committee memberBranko Dmitrović (član povjerenstva)
GranterJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Osijek
Defense date and country2017-09-25, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract
Cilj istraživanja: Imunohistokemijski usporediti pojavnost HER1 i e-cadherina u tumorskim stanicama trostruko negativnog karcinoma dojke (TNBC) i u ostalim karcinomima dojke. Ustroj studije: Retrospektivna studija. Ispitanici i metode: Istraživanje je provedeno na 30 uzoraka tumorskog tkiva pacijentica kod kojih je dijagnosticiran TNBC i 30 uzoraka tumorskog tkiva ostalih karcinoma dojke. Imunohistokemijska pojavnost HER1 i e-cadherina procijenjena je semikvantitativno prema postotku pozitivno obojenih stanica: 0 (negativno), 1+ (do 11 % pozitivnih tumorskih stanica), 2+ (11-30 % tumorskih stanica), 3+ (30 % i više pozitivnih tumorskih stanica). Rezultati: Statistički značajno bilo je više slabo diferenciranih tumora u skupini trostruko negativnog karcinom dojke (P < 0,001). Bolesnice oboljele od trostruko negativnog karcinoma dojke su značajnije mlađe dobne skupine od bolesnica oboljelih od ostalih tipova raka dojke (P = 0,03). Statistički značajno je veća mitotska aktivnost u skupini trostruko negativnih karcinoma dojke u odnosu na kontrolnu skupinu (P < 0,001). U obje skupine nema značajnih razlika u ekspresiji HER1 i e-cadherina prema veličini tumora, nazočnosti metastaza u limfnim čvorovima, stupnju diferencijacije tumora, dobi bolesnica, ekspresiji hormonskih (ER i PR) receptora, amplifikaciji HER2 gena i mitotskoj aktivnosti tumora. Zaključak: Pojavnost HER1 (HER1) receptora i e-cadherina u trostruko negativnom karcinomu dojke u odnosu na ostale podskupine karcinoma dojke ne pokazuje statistički značajne razlike što upućuje na zaključak kako HER1 i e-cadherin nemaju značajniji terapijski potencijal u ovoj skupini raka dojke.
Abstract (english)
PARTICIPANTS AND METHODS: The study was conducted on 30 samples of tumour tissue samples from patients diagnosed with TNBC and 30 tumour tissue samples of other breast cancers. Immunohistochemistry of HER1 and e-cadherin was evaluated semi-quantitatively, according to the percentage of positively coloured cells: 0 (negative), 1+ (up to 11% of positive tumour cells), 2+ (11 – 30% tumour cells), 3+ (30% and more positive tumour cells). RESULTS: Statistically there were significantly fewer poorly differentiated tumours in the group of triple negative breast cancer (P<0.001). Patients suffering from triple negative breast cancer are significantly younger than patients with other breast cancer types (P=0.03). There is statistically significantly higher mitotic activity in the group of triple negative breast cancer compared to the control group (P<0.001). There are no significant differences in the expression of HER1 and e-cadherin in tumour size, lymph node metastases, degree of tumour differentiation, patients’ age, hormone (ER and PR) receptor expression, HER2 gene amplification, and mitotic tumour activity. CONCLUSION: The occurrence of HER1 (HER1) receptors and e-cadherin in triple negative breast cancer does not show statistically significant differences in comparison to other breast cancer subgroups, suggesting that so far HER1 and e-cadherin have no significant therapeutic potential.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:152:222472
Study programmeTitle: University graduate study
Study programme type: university
Study level: graduate
Academic / professional title: magistar/magistra medicinsko laboratorijske dijagnostike (magistar/magistra medicinsko laboratorijske dijagnostike)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2018-05-21 11:54:40